Myriad Genetics (MYGN) Misses Q4 EPS by 6c, Guidance Misses Consensus

August 13, 2019 4:05 PM

Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.41, $0.06 worse than the analyst estimate of $0.47. Revenue for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found